JP2018523105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523105A5 JP2018523105A5 JP2017563088A JP2017563088A JP2018523105A5 JP 2018523105 A5 JP2018523105 A5 JP 2018523105A5 JP 2017563088 A JP2017563088 A JP 2017563088A JP 2017563088 A JP2017563088 A JP 2017563088A JP 2018523105 A5 JP2018523105 A5 JP 2018523105A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- subject
- crbn
- ratio
- therapeutic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170099P | 2015-06-02 | 2015-06-02 | |
| US62/170,099 | 2015-06-02 | ||
| US201562237905P | 2015-10-06 | 2015-10-06 | |
| US62/237,905 | 2015-10-06 | ||
| PCT/US2016/035198 WO2016196580A1 (en) | 2015-06-02 | 2016-06-01 | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523105A JP2018523105A (ja) | 2018-08-16 |
| JP2018523105A5 true JP2018523105A5 (https=) | 2019-05-16 |
| JP6585737B2 JP6585737B2 (ja) | 2019-10-02 |
Family
ID=57441615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563088A Active JP6585737B2 (ja) | 2015-06-02 | 2016-06-01 | セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10338077B2 (https=) |
| EP (1) | EP3304076A4 (https=) |
| JP (1) | JP6585737B2 (https=) |
| WO (1) | WO2016196580A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| WO2017053555A1 (en) | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| KR20180095094A (ko) | 2016-01-08 | 2018-08-24 | 셀진 코포레이션 | 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도 |
| EP3422002B1 (de) * | 2017-06-26 | 2020-04-08 | Bioscientia Institut für Medizinische Diagnostik GmbH | Screeningverfahren zur diagnose einer hämatologischen neoplasie |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AU2019352504A1 (en) * | 2018-10-04 | 2021-05-13 | Alfred Health | Methods for monitoring response to treatment |
| AU2019391016B2 (en) * | 2018-12-03 | 2025-05-29 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| KR20210106437A (ko) * | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| EP4271995A4 (en) * | 2020-12-31 | 2024-11-20 | Elephas Biosciences Corporation | EX VIVO SYSTEMS AND METHODS FOR DETERMINING THE EFFECT OF A DRUG OR OTHER AGENT ON A TISSUE |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9662319B2 (en) * | 2011-03-11 | 2017-05-30 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs |
| AU2012249491B2 (en) | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| EP2892537A1 (en) * | 2012-09-10 | 2015-07-15 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| EP2991651A1 (en) * | 2013-05-03 | 2016-03-09 | Celgene Corporation | Methods for treating cancer using combination therapy |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| EP3077547A4 (en) | 2013-12-06 | 2017-11-08 | Celgene Corporation | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| WO2017024019A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US20180231561A1 (en) | 2015-08-12 | 2018-08-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| WO2017053555A1 (en) | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| KR20180095094A (ko) | 2016-01-08 | 2018-08-24 | 셀진 코포레이션 | 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도 |
-
2016
- 2016-06-01 WO PCT/US2016/035198 patent/WO2016196580A1/en not_active Ceased
- 2016-06-01 EP EP16804297.6A patent/EP3304076A4/en active Pending
- 2016-06-01 JP JP2017563088A patent/JP6585737B2/ja active Active
- 2016-06-01 US US15/170,789 patent/US10338077B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523105A5 (https=) | ||
| Vermeire et al. | Laboratory markers in IBD: useful, magic, or unnecessary toys? | |
| Willumsen et al. | Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls | |
| JP2017524130A5 (https=) | ||
| Avram et al. | The density and type of MECA‐79‐positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma | |
| JP2013179945A (ja) | 分類予測を使用した肺障害についての診断 | |
| Ke et al. | Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria | |
| Zhang et al. | Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma | |
| KR20190021252A (ko) | c-MAF 상태에 기초한 유방암의 치료 | |
| Ward et al. | Evaluation of serum and tissue levels of VAP-1 in colorectal cancer | |
| CN106662543B (zh) | 肺癌患者中的非侵入性基因突变检测 | |
| US10585102B2 (en) | Characterization of cancer using detection of activated leukocyte cell adhesion molecule (ALCAM) shedding | |
| Arakawa et al. | Clinical significance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell carcinoma | |
| Ge et al. | Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma | |
| Edfeldt et al. | DcR3, TFF3, and midkine are novel serum biomarkers in small intestinal neuroendocrine tumors | |
| JP2018529931A5 (https=) | ||
| Yan et al. | Significance of tumour cell HLA‐G5/‐G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients | |
| JP2021523379A5 (https=) | ||
| Yan et al. | High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients | |
| Krikelis et al. | Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients | |
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| Štemberger et al. | Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma | |
| Sun et al. | The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma | |
| Srivastava et al. | Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer | |
| Liao et al. | Astrocyte elevated gene-1 (AEG-1) is a marker for aggressive salivary gland carcinoma |